Bulletin
Investor Alert

ICU Medical Inc.

NAS: ICUI

GO

Set Alerts

Market Index

Overview Profile Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders
/marketstate/country/us
ICU Medical Inc.

After Hours

 --Quotes are delayed by 20 min

Jun 30, 2022, 4:39 p.m.

ICUI
/zigman2/quotes/208026181/composite

$

164.39

Change

0.00 0.00%

Volume

Volume 6,579

Quotes are delayed by 20 min

/zigman2/quotes/208026181/composite

Today's close

$ 168.11

$ 164.39

Change

-3.72 -2.21%

Day low

Day high

$163.49

$167.22

Open

52 week low

52 week high

$158.60

$282.00

Open

Company Description

ICU Medical, Inc. engages in the development, manufacture, and sale of innovative medical devices used in vascular therapy and critical care applications. Its product portfolio includes intravenous smart pumps, sets, connectors, closed transfer devices for hazardous drugs, cardiac monitoring systems...

ICU Medical, Inc. engages in the development, manufacture, and sale of innovative medical devices used in vascular therapy and critical care applications. Its product portfolio includes intravenous smart pumps, sets, connectors, closed transfer devices for hazardous drugs, cardiac monitoring systems, IV solutions, IV smart pumps with pain management and safety software technology, dedicated and non-dedicated IV sets and needle-free connectors. The company was founded by George A. Lopez in 1984 and is headquartered in San Clemente, CA.

Valuation

P/E Current

35.50

P/E Ratio (with extraordinary items)

96.17

P/E Ratio (without extraordinary items)

50.12

Price to Sales Ratio

3.93

Price to Book Ratio

3.13

Price to Cash Flow Ratio

19.32

Enterprise Value to EBITDA

14.73

Enterprise Value to Sales

2.27

Efficiency

Total Asset Turnover

0.72

Liquidity

Current Ratio

5.07

Quick Ratio

3.62

Cash Ratio

2.83

Profitability

Gross Margin

36.35

Operating Margin

10.48

Pretax Margin

9.36

Net Margin

7.84

Return on Assets

5.66

Return on Equity

6.61

Return on Total Capital

8.58

Capital Structure

Total Debt to Total Assets

2.43

Officers and Executives

Name Age Officer Since Title
Mr. Vivek Jain 47 2014 Chairman & Chief Executive Officer
Mr. Christian Voigtlander 51 2017 Vice President-Business Development
Mr. Brian M. Bonnell - 2018 Vice President-Finance
Mr. Krishna Uppugonduri - 2015 VP-Quality, Medical & Regulatory Affairs
Mr. Daniel Woolson 43 2017 Vice President & General Manager-Infusion Systems

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
05/23/2022 Vivek Jain
Chairman and CEO; Director 		30   Gift at $0 per share. 0
05/13/2022 Elisha Wade Finney
Director 		743   Gift at $0 per share. 0
05/12/2022 George A. Lopez
Director 		17   Acquisition at $174.66 per share. 2,969
05/12/2022 George A. Lopez
Director 		9,329   Acquisition at $174.17 per share. 1,624,831
05/12/2022 George A. Lopez
Director 		7,092   Acquisition at $173.07 per share. 1,227,412
05/12/2022 George A. Lopez
Director 		4,917   Acquisition at $172.24 per share. 846,904
05/12/2022 George A. Lopez
Director 		4,480   Acquisition at $170.79 per share. 765,139
05/12/2022 Virginia Sanzone
VP, General Counsel 		750   Disposition at $173.56 per share. 130,170
05/12/2022 Elisha Wade Finney
Director 		217   Disposition at $170.53 per share. 37,005
05/11/2022 David C. Greenberg
Director 		433   Derivative/Non-derivative trans. at $0 per share. 0
05/11/2022 David F. Hoffmeister
Director 		433   Derivative/Non-derivative trans. at $0 per share. 0
05/11/2022 Donald M. Abbey
Director 		433   Derivative/Non-derivative trans. at $0 per share. 0
05/11/2022 Elisha Wade Finney
Director 		433   Derivative/Non-derivative trans. at $0 per share. 0
05/11/2022 Laurie Hernandez
Director 		352   Derivative/Non-derivative trans. at $0 per share. 0
05/11/2022 Kolleen T. Kennedy
Director 		129   Derivative/Non-derivative trans. at $0 per share. 0
03/08/2022 Vivek Jain
Chairman and CEO; Director 		1,328   Derivative/Non-derivative trans. at $0 per share. 0
03/08/2022 Christian B. Voigtlander
Chief Operating Officer 		1,163   Derivative/Non-derivative trans. at $0 per share. 0
03/08/2022 Daniel Woolson
VP, GM-Infusion Capital 		894   Derivative/Non-derivative trans. at $0 per share. 0
03/08/2022 Brian M. Bonnell
Chief Financial Officer 		1,163   Derivative/Non-derivative trans. at $0 per share. 0
03/08/2022 Kevin J. McGrody
Chief Accounting Officer 		442   Derivative/Non-derivative trans. at $0 per share. 0
03/08/2022 Virginia Sanzone
VP, General Counsel 		1,196   Derivative/Non-derivative trans. at $0 per share. 0
03/08/2022 Vivek Jain
Chairman and CEO; Director 		2,524   Derivative/Non-derivative trans. at $0 per share. 0
03/08/2022 Christian B. Voigtlander
Chief Operating Officer 		2,209   Derivative/Non-derivative trans. at $0 per share. 0
03/08/2022 Daniel Woolson
VP, GM-Infusion Capital 		2,020   Derivative/Non-derivative trans. at $0 per share. 0
03/08/2022 Brian M. Bonnell
Chief Financial Officer 		2,209   Derivative/Non-derivative trans. at $0 per share. 0
03/08/2022 Kevin J. McGrody
Chief Accounting Officer 		841   Derivative/Non-derivative trans. at $0 per share. 0
03/08/2022 Virginia Sanzone
VP, General Counsel 		2,272   Derivative/Non-derivative trans. at $0 per share. 0
03/06/2022 Vivek Jain
Chairman and CEO; Director 		760   Derivative/Non-derivative trans. at $242.93 per share. 184,626
03/06/2022 Vivek Jain
Chairman and CEO; Director 		932   Derivative/Non-derivative trans. at $242.93 per share. 226,410
03/06/2022 Christian B. Voigtlander
Chief Operating Officer 		816   Derivative/Non-derivative trans. at $242.93 per share. 198,230
03/06/2022 Christian B. Voigtlander
Chief Operating Officer 		760   Derivative/Non-derivative trans. at $242.93 per share. 184,626
03/06/2022 Daniel Woolson
VP, GM-Infusion Capital 		628   Derivative/Non-derivative trans. at $0 per share. 0
03/06/2022 Daniel Woolson
VP, GM-Infusion Capital 		639   Derivative/Non-derivative trans. at $242.93 per share. 155,232
03/06/2022 Brian M. Bonnell
Chief Financial Officer 		816   Derivative/Non-derivative trans. at $242.93 per share. 198,230
03/06/2022 Brian M. Bonnell
Chief Financial Officer 		380   Derivative/Non-derivative trans. at $242.93 per share. 92,313
03/06/2022 Kevin J. McGrody
Chief Accounting Officer 		466   Derivative/Non-derivative trans. at $242.93 per share. 113,205
03/06/2022 Kevin J. McGrody
Chief Accounting Officer 		532   Derivative/Non-derivative trans. at $242.93 per share. 129,238
03/06/2022 Virginia Sanzone
VP, General Counsel 		839   Derivative/Non-derivative trans. at $242.93 per share. 203,818
03/06/2022 Virginia Sanzone
VP, General Counsel 		760   Derivative/Non-derivative trans. at $242.93 per share. 184,626
03/06/2022 Vivek Jain
Chairman and CEO; Director 		1,444   Derivative/Non-derivative trans. at $0 per share. 0
03/06/2022 Vivek Jain
Chairman and CEO; Director 		1,772   Derivative/Non-derivative trans. at $0 per share. 0
03/06/2022 Christian B. Voigtlander
Chief Operating Officer 		1,551   Derivative/Non-derivative trans. at $0 per share. 0
03/06/2022 Christian B. Voigtlander
Chief Operating Officer 		1,444   Derivative/Non-derivative trans. at $0 per share. 0
03/06/2022 Daniel Woolson
VP, GM-Infusion Capital 		1,418   Derivative/Non-derivative trans. at $0 per share. 0
03/06/2022 Daniel Woolson
VP, GM-Infusion Capital 		1,444   Derivative/Non-derivative trans. at $0 per share. 0
03/06/2022 Brian M. Bonnell
Chief Financial Officer 		1,551   Derivative/Non-derivative trans. at $0 per share. 0
03/06/2022 Brian M. Bonnell
Chief Financial Officer 		722   Derivative/Non-derivative trans. at $0 per share. 0
03/06/2022 Kevin J. McGrody
Chief Accounting Officer 		886   Derivative/Non-derivative trans. at $0 per share. 0
03/06/2022 Kevin J. McGrody
Chief Accounting Officer 		1,011   Derivative/Non-derivative trans. at $0 per share. 0
03/06/2022 Virginia Sanzone
VP, General Counsel 		1,595   Derivative/Non-derivative trans. at $0 per share. 0
03/06/2022 Virginia Sanzone
VP, General Counsel 		1,444   Derivative/Non-derivative trans. at $0 per share. 0
03/03/2022 Vivek Jain
Chairman and CEO; Director 		36,000   Disposition at $240 per share. 8,640,000
03/03/2022 Vivek Jain
Chairman and CEO; Director 		36,000   Derivative/Non-derivative trans. at $58.79 per share. 2,116,440
12/30/2021 Vivek Jain
Chairman and CEO; Director 		1,159   Disposition at $240 per share. 278,160
12/30/2021 Vivek Jain
Chairman and CEO; Director 		1,159   Derivative/Non-derivative trans. at $58.79 per share. 68,137
12/29/2021 Vivek Jain
Chairman and CEO; Director 		10,677   Disposition at $240 per share. 2,562,480
12/29/2021 Vivek Jain
Chairman and CEO; Director 		10,677   Derivative/Non-derivative trans. at $58.79 per share. 627,700
12/28/2021 Vivek Jain
Chairman and CEO; Director 		164   Disposition at $240 per share. 39,360
12/28/2021 Vivek Jain
Chairman and CEO; Director 		164   Derivative/Non-derivative trans. at $58.79 per share. 9,641
/news/latest/company/us/icui

MarketWatch News on ICUI

  1. Edwards Lifesciences Corp. stock falls Friday, still outperforms market

    5:52 p.m. Feb. 11, 2022

    - MarketWatch Automation

  2. Edwards Lifesciences Corp. stock falls Thursday, still outperforms market

    5:52 p.m. Feb. 10, 2022

    - MarketWatch Automation

  4. Edwards Lifesciences Corp. stock rises Tuesday, still underperforms market

    5:52 p.m. Feb. 8, 2022

    - MarketWatch Automation

  5. Edwards Lifesciences Corp. stock falls Monday, underperforms market

    5:52 p.m. Feb. 7, 2022

    - MarketWatch Automation

  6. Edwards Lifesciences Corp. stock rises Friday, outperforms market

    5:52 p.m. Feb. 4, 2022

    - MarketWatch Automation

  8. Edwards Lifesciences Corp. stock rises Wednesday, outperforms market

    5:53 p.m. Feb. 2, 2022

    - MarketWatch Automation

  9. Edwards Lifesciences Corp. stock falls Tuesday, underperforms market

    5:53 p.m. Feb. 1, 2022

    - MarketWatch Automation

  10. Edwards Lifesciences Corp. stock rises Monday, outperforms market

    5:52 p.m. Jan. 31, 2022

    - MarketWatch Automation

  12. Edwards Lifesciences Corp. stock falls Thursday, underperforms market

    5:53 p.m. Jan. 27, 2022

    - MarketWatch Automation

  15. Edwards Lifesciences Corp. stock falls Monday, underperforms market

    5:53 p.m. Jan. 24, 2022

    - MarketWatch Automation

  16. Edwards Lifesciences Corp. stock falls Friday, underperforms market

    5:53 p.m. Jan. 21, 2022

    - MarketWatch Automation

  17. Edwards Lifesciences Corp. stock falls Thursday, still outperforms market

    5:52 p.m. Jan. 20, 2022

    - MarketWatch Automation

  18. Edwards Lifesciences Corp. stock outperforms market on strong trading day

    5:53 p.m. Jan. 19, 2022

    - MarketWatch Automation

  19. Edwards Lifesciences Corp. stock falls Tuesday, underperforms market

    5:53 p.m. Jan. 18, 2022

    - MarketWatch Automation

  20. Edwards Lifesciences Corp. stock falls Friday, underperforms market

    5:53 p.m. Jan. 14, 2022

    - MarketWatch Automation

  21. Loading more headlines...
/news/nonmarketwatch/company/us/icui

Other News on ICUI

  1. Bausch + Lomb: Shares Deserve Some Upside

    8:00 a.m. June 9, 2022

    - Seeking Alpha

  4. ICU Medical (ICUI) Surpasses Q1 Earnings Estimates

    5:45 p.m. May 9, 2022

    - Zacks.com

  5. 10-Q: ICU MEDICAL INC/DE

    5:17 p.m. May 9, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  6. Notable earnings after Monday's close

    5:35 p.m. May 8, 2022

    - Seeking Alpha

  8. ICU Medical (ICUI) Investor Presentation - Slideshow

    3:08 p.m. March 29, 2022

    - Seeking Alpha

  13. Buy These 4 Low-Beta Stocks to Combat the Choppy Market

    6:53 a.m. March 23, 2022

    - Zacks.com

  15. Meridian Bioscience: Deceptively Priced

    9:27 a.m. March 14, 2022

    - Seeking Alpha

  20. 10-K: ICU MEDICAL INC/DE

    7:56 p.m. Feb. 25, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  21. Loading more headlines...

At a Glance

ICU Medical, Inc.

951 Calle Amanecer

San Clemente, California 92673-6212

Phone

1 9493662183

Industry

Medical Equipment/Supplies

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2022

View SEC Filings

Revenue

$1.32B

Net Income

$103.14M

Employees

8,500

Annual Report for ICUI

/news/pressrelease/company/us/icui

Press Releases on ICUI

  2. Monday 5/16 Insider Buying Report: NTRA, ICUI

    10:42 a.m. May 16, 2022

    - MarketNewsVideo.com

  4. ICU Medical Announces First Quarter 2022 Results

    4:05 p.m. May 9, 2022

    - GlobeNewswire

  21. Loading more headlines...
Link to MarketWatch's Slice.